Alkermes applies its scientific expertise and technological know-how to develop innovative medicines designed to help patients with serious, chronic conditions better manage their disease.
Alkermes to Present at the Evercore ISI 2nd Annual HealthCONx Conference Read More
Alkermes Completes Acquisition of Rodin Therapeutics Read More
Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder Read More